The present results support the hypothesis that the SUMO E3 ligase PIASy mediates high glucose-induced activation of NF-κB inflammatory signaling, suggesting that PIASy may be a potential therapeutic target of DN. Here, NFKB1 is linked to liver dysplastic nodule.